




SUPPLEMENTARY FIGURES




Supplementary Figure 1. Identification of BMECs. The representative CD31-positive and vWF-positive cells were identified as BMECs.



Supplementary Figure 2. Effect of ESWT on HUVECs treated with GCs. ECs were subjected to ESWT with 0.05 mJ/mm^2 , 1000 shots followed by DEX with $180 \mu\text{M}$. (A) cell proliferation confirmed by EdU assay; (B) apoptosis rate of assessed through Annexin V-FITC/PI; (C) migration ability evaluated by wound healing assay; (D) migration ability evaluated by Transwell assay; (E) angiogenesis ability evaluated by tube formation assay. $n=3$ ** $P < .01$, *** $P < .001$.



Supplementary Figure 3. Effect of miR-135b on HUVECs treated with GCs. After transfection of inhibitor miR-135b, ECs were subjected to ESWT with 0.05 mJ/mm^2 , 1000 shots followed by DEX with $180 \mu\text{M}$. (A) cell viability examined by CCK-8 analysis; (B) cell proliferation confirmed by EdU assay; (C) apoptosis rate of assessed through Annexin V-FITC/PI; (D) migration ability evaluated by wound healing assay; (E) migration ability evaluated by Transwell assay; (F) angiogenesis ability evaluated by tube formation assay. $n=3$ ** $P < .01$, *** $P < .001$.



Supplementary Figure 4. Effect of FOXO1 on HUVECs treated with GCs. After overexpression of FOXO1, ECs were subjected to ESWT with 0.05 mJ/mm^2 , 1000 shots followed by DEX with $180 \mu\text{M}$. (A) cell viability examined by CCK-8 analysis; (B) cell proliferation confirmed by EdU assay; (C) apoptosis rate of assessed through Annexin V-FITC/PI; (D) migration ability evaluated by wound healing assay; (E) migration ability evaluated by Transwell assay; (F) angiogenesis ability evaluated by tube formation assay. $n=3$ ** $P < .01$, *** $P < .001$.